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Introduction 
Gastritis, duodenitis and peptic ulceration are common chronic conditions. 
Their aetiology and pathogenesis are not completely understood. Thus 
much excitement was generated in 1983 when Warren and Marshall found 
curved or spiral campylobac~er-like bacteria in endoscopic antral mucosa 
from patients with gastritis and peptic ulceration. It was suggested that 
these bacteria might cause these diseases; an association which has now 
been supported by various studies (Rauws and Tytgat, 1989). 
In 1989, information about H-pylori infection started being gathered in 
Malta. This project was thus aimed towards gathering data on the 
incidence, clinical aspects and treatment of this association. 
Methodology 
Studyl 
Prevalence of Helicobacter pylori in the Maltese Islands 
In the 1989 - 1990 period, endoscopy procedures were conducted by Dr. A. 
Caruana Galizia et al at the Endoscopy Unit of St. Luke's Hospital. The 
surgical procedures involved Fibreoptic-oesophago-gastro-duodenoscopy 
(FOGO) and results were collected and kept at the Endoscopy Unit. A 
survey was conducted in Jan - Feb 1990 using FOGO, on 90 consecutive 
patients to check the incidence of H.pylori in such patients using the CLO 
Teste. The association of Helicobacter pylori colonization with 
inflammation and ulceration was also studied. 
Study II 
pinical experience with this association 
From over 300 endoscopies performed over the period March '90 - June '91, 
50 patients were eligible to be included in this study, with the rest being 
eliminated by the Inclusion/Exclusion criteria. 
The effectiveness of Triple Therapy use on H.pylori colonization and the 
latter's subsequent iI).fluence on acid peptic disease (Le. peptic ulceration, 
gastritis, and duodenitis) ]Nere studied. The prevalence of predisposing 
factors (alcohol, smoking and NSAIDs) in these patients were also 
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assessed to find whether these factors had any influence on association or 
treatment. 
Study III 
Patient Interview 
40 patients from a list of 50 patients for the period March '90 - June '91, 
whose diagnosis was confirmed by CLO Test and endoscopy, were 
interviewed at M2 Ward St. Luke's Hospital. Information on i) 
symptoms before Triple Therapy, ii) symptoms after Triple Therapy, iii) 
Drug-related problems, iv) Relationships with pharmacists/doctors and 
v) Effect of disease/treatment on quality of life was obtained. 
Results 
Study 1 
In this study, conducted in January - February '90, 90 patients were 
endoscoped and urease tested for incidence of H.pylori colonization - ~. 
males (60%) and 36 females (40%). In these patients ages ranged from 19 
to 76 years. As regards the CLO Test, 29 males (54%) and 15 females 
(42%) were urease positive with a total prevalence of 49% i.e. 44 out of 
90 patients. 
Endoscopic findings in these patients found that 40 patients had evidence 
of actual gastric or duodenal ulceration or endoscopic evidence of gastritis 
or duodenitis. In these 40 patients, 26 patients (65%) were colonized by 
this micro-organism. The remaining 50 patients were divided into those 
with normal (n=2U and abnormal histology (n=29). In the latter, 46% 
were urease positive while in the 21 patients with normal histology, 
only 24% tested positive to eLO Test. 
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Finally, urease positive test results obtained for H. pylori were most 
frequent in the following groups of patients: 
Description 
Patients with actual or previous 
duodenal ulcer and with definite 
chronic gastritis 
Patients with actual or previous 
duodenal ulcer 
Patients with definite histological 
changes of chronic atrophic 
gastritis 
Patients with actual or previous gastric 
ulcer and with definite chronic gastritis 
Study II 
Patients % 
------------- -------
90utofl0 90 
12 out of 15 80 
29 out of 43 67 
50utofl0 50 
-------------
-------
The patients included in this study were all CLO+ve and had 
endoscopical evidence of inflammation/ulceration (Inclusion Criteria). 
40% (n=20) of the patients had gastritis or duodenitis while 60% (n=30) 
have gastric or duodenal ulceration. 
27 patients turned up for their re-endoscopy and confirmed that they had 
completed their Triple Therapy course (Exclusion Criteria). Triple 
Therapy consists of De-Nol (tri-potassium di-citrato bismulhate) 120mg 
4 times daily for 4 weeks, Amoxycillin 250mg 3 times daily 1 - 14 days 
and Metronidazole 200mg 3 times daily 15 - 28 days. The CLO Test was 
performed in 24 patients, the remaining patients (n=3) were not tested for 
H.pylori colonization because at the time of investigation the test strips 
were not available. 
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CLOTest No % Male Female 
-----------------
------- ------- --------
---------
Urease -ve 16 67 11 5 
Urease+ve 8 33 3 5 
TOTAL 24 100 14 10 
-----------------
------- ------- -------- ---------
Endoscopic Evidence - The patients were subdivided into 3 groups: 
Group I: 
Group II: 
Group III: 
Patients with normal endoscopic findings 
Patients having endoscopic evidence of gastritis or 
duodenitis only 
Patients with gastric or duodenal ulceration 
-G~~~p-r-p~TriPI~------%-----p~s~Tripl;-l--o/~-I-u~;;~~~~--
Therapy Therapy 
~~~~~t~~~!~~~~~~ ~ ~~~~~~~~~~1~~1~~1~~~~~:~~~~~ 
* N.B. 2 CLO Test results not available for Group II patients and 1 CLO 
Test result not available for Group III patients 
33% (n=9) of patients stated that they drank alcohol and smoked while 
taking their treatment while another 6 patients either smoked (n=3) or 
drank alcohol (n=3) bringing the total to 55% (n=15). The influence of 
these predisposing factors on H.pylori colonization and Triple Therapy 
were tabulated: 
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Pre-Triple CLO+ve Post-Triple I CLO+ve 
Therapy Therapy 
---------t---------- ----------- ----------1----------Group I 0 0 4 0 Group II 6 6 8 2* 
Group III 9 9 3 1* 
--------- ---------- ----------- ---------- ----------
* N.B. 2 CLO Test results were not available for Group II patients and 1 
CLO Test result was not available for Group III patients 
5htdy III 
Interviews showed that: 
i) All patients prior to Triple Therapy have experienced epigastric 
pain with almost half (47.5%) of patients having heartburn as 
secohdary symptom. 67% (n=27) of patients felt pain on a daily 
basis with the duration running for several hours. All patients had 
taken either Antacids or H2-Receptor Antagonists to Triple 
Therapy, in those patients (n=27) who had taken both, 63% (n=17) 
found H2RA better than antacids symptom-wise. 
i i) After Triple Therapy use, symptoms recurred again in 42.5% (n=17) 
of patients. In these patients, 65% (n=13) remained symptomless 
for more than a year. Whenever these patients had a recurrence, 
the severity, duration and frequency of the symptoms were found to 
be less than before. 
iii) The highest percentage for drug-related problems was of 85% 
(n=34) having a common side-effect of De-Nol, stools turning 
black. There was no evidence of serious side-effects such as 
encephalopa thy. 
i v) 37.5% (n= 15) wanted pharmacists to play an advisory role, 90% 
of the patients attended out-patient clinic regularly and 92.5% 
had faith in their medicines. 
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v) Disease/Treatment had the greatest impact on their emotions 
(100%) with the second largest influence being on food in 73% of 
patients. 
Discussion 
Results indicate that the incidence of H.pylori in Malta is not rare and it 
affects more males than females. There is a definite association between 
H.pylori colonization of gastro-duodenal mucosa and acid-peptic disease. 
The efficacy of Triple Therapy in H.pylori eradication was somewhat 
successful and definitely higher than that obtained in studies with 
antimicrobials or H2-receptor antagonists (HirschI et aI, 1988). The 
micro-organism's removal had a consequently beneficial effect on the 
gastro-duodenal mucosa and underlying tissues. In addition, the 
symptomatic relief achieved by Triple Therapy ensure its future 
therapeutic role as an alternative to more traditional treatment. Also 
predisposing factors such as smoking and alcohol were found to have no 
influence on Triple Therapy eradication of H.pylori. The most serious 
side-effect of De-Nol, encephalopathy, was absent agreeing with the 
Amsterdam study (Rauws and Tytgat, 1989) that no serious side-effects·' 
arise with the Bismuth salt if it is limited for short treatment periods. 
There were no problems of compliance in these patients and after Triple 
Therapy there was a marked improvement in their quality of life. 
Conclusion 
Study I shows the need to know the incidence of H.pylori colonization in 
the general population, now that there is overwhelming evidence of its 
pathogenic role in acid peptic disease. The use of serum anliboLly assays 
usually IgG, specific to H.pylori would make mass screening possible 
(Rathbone and Heatley 1989). This technique, however is not in current 
use at St. Luke's Hospital. Study II shows the efficacy of Triple Therapy 
use in patients with these conditions and the need for this drug treatment 
to succeed other drug therapy currently in use. However, its success rate 
on H.pylori eradication proves the need for further improvement and 
research for better drugs. Study III shows that pharmacists and doctors 
should play a more active role in informing their patients how to 
understand and manage better their disease. 
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